Although an improvement on trend from our first quarter, our sales performance this quarter is still not at the level we know we can achieve,

Sales are down by half, which is a slight improvement, but really it's still very grim.

Our September sales performance was softer than expected. However, when you consider our exceptional sales performance in July and August, lean inventories, and the competitive environment, we expected there would be some weakening in September sales.

We'll continue to adjust our staffing levels to the sales performance we have.

Our performance continues to be driven by robust sales of our innovative oncology products which have helped nearly double our revenues in a three-year time period.

Our performance was extremely strong reporting record sales for the fourth-quarter and fiscal year.